INDP:NSD-Indaptus Therapeutics Inc (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 1.06

Change

-0.11 (-9.40)%

Market Cap

USD 0.01B

Volume

0.06M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-26 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
REGN Regeneron Pharmaceuticals Inc

+8.81 (+0.85%)

USD 126.22B
VRTX Vertex Pharmaceuticals Inc

+1.39 (+0.30%)

USD 120.00B
ALNY Alnylam Pharmaceuticals Inc

+1.84 (+0.67%)

USD 35.01B
ARGX argenx NV ADR

-24.43 (-4.45%)

USD 32.83B
MRNA Moderna Inc

+0.29 (+0.46%)

USD 25.25B
BGNE BeiGene Ltd

+5.81 (+2.81%)

USD 22.45B
SMMT Summit Therapeutics PLC

+0.17 (+0.75%)

USD 17.92B
RPRX Royalty Pharma Plc

+0.54 (+1.95%)

USD 16.34B
UTHR United Therapeutics Corporatio..

-1.79 (-0.50%)

USD 15.71B
PCVX Vaxcyte Inc

-2.02 (-1.78%)

USD 14.50B

ETFs Containing INDP

INDL Direxion Daily MSCI India.. 50.17 % 1.01 %

+0.62 (+2.12%)

USD 0.11B
DWCR 10.18 % 0.79 %

N/A

N/A
3010:HK iShares MSCI AC Asia ex J.. 4.18 % 0.00 %

+1.50 (+2.12%)

USD 2.66B
DMCY Democracy International F.. 0.00 % 0.00 %

+0.57 (+2.12%)

USD 7.93M

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -39.77% 35% F 21% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -39.77% 35% F 21% F
Trailing 12 Months  
Capital Gain -61.45% 23% F 14% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -61.45% 23% F 14% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -14.01% 37% F 22% F
Dividend Return -14.01% 37% F 21% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 33.79% 79% B- 55% F
Risk Adjusted Return -41.44% 30% F 20% F
Market Capitalization 0.01B 19% F 15% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector